Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
Matulonis U, Shapira R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Wu H, Keefe S, Stein K, Ledermann J. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Journal Of Clinical Oncology 2020, 38: 6005-6005. DOI: 10.1200/jco.2020.38.15_suppl.6005.Peer-Reviewed Original ResearchRecurrent advanced ovarian cancerAdvanced ovarian cancerPD-L1 expressionECOG PS 0Prior chemotherapy linesCohort AChemotherapy linesMedian OSPS 0Ovarian cancerFront-line platinum-based therapyAdvanced recurrent ovarian cancerHigh PD-L1 expressionHigh-grade serous diseaseProtocol-specified final analysisTumor PD-L1 expressionTreatment-related AEsPrimary peritoneal cancerRecurrent ovarian cancerTreatment-free intervalTreatment-related deathsModest antitumor activityModest clinical activityNew safety signalsPrimary study endpoint